Anton | Specter (@Im_Specter) header
Anton | Specter (@Im_Specter) profile picture

Recherche actions indépendante | Small & mid caps |

Analyses buy-side Substack👇
Joined July 2016
Photo by Anton | Specter (@Im_Specter)Photo by Anton | Specter (@Im_Specter)Photo by Anton | Specter (@Im_Specter)Photo by Anton | Specter (@Im_Specter)Photo by Anton | Specter (@Im_Specter)Photo by Anton | Specter (@Im_Specter)Photo by Anton | Specter (@Im_Specter)Photo by Anton | Specter (@Im_Specter)Photo by Anton | Specter (@Im_Specter)Photo by Anton | Specter (@Im_Specter)
Anton | Specter retweeted
$RX.V — BioSyent | Q3 2026 Results Specialty pharma and oral health company that in-licenses and markets proven products in canada and abroad, now with oral science inc. on board. 📊 Q3 2026 Highlights: • Revenue: $20.1M (+64% yoy) • Gross margin: 70% (vs 76%) as lower-margin oral health joins the mix • EBITDA: $5.6M (+53%), 28% margin • Net income: $2.86M (+7%), diluted EPS $0.25 (+8%) • Operating cash flow: $6.0M (vs $2.8M) • Cash & ST investments: $16.0M | Total debt: $2.0M, repaid in full on Oct 1 🏥 Segments: • Pharmaceutical: $11.5M (+5%) • Oral health: $7.8M, $1.6M EBITDA in its second full quarter • Insecticide: $0.7M (-39%) 💰 Shareholder Returns: • $1.7M of buybacks in q3, 326,500 shares cancelled ytd • Dividend: $0.055/quarter, next paid Dec 15 • TTM return on average equity: 23% 🔮 Pipeline: • Thyconvi launch in canada planned for q1 2027 The oral science deal is doing what it was bought to do: 64% revenue growth and a 53% jump in EBITDA. net income only rose 7% because of $825K of quarterly amortization on acquired intangibles, so cash flow tells the better story. with the acquisition debt gone, biosyent is back to a debt-free balance sheet while still buying back stock, though $6.0M of contingent consideration is still owed on the deal. Full analysis: investorlens.io/stocks/RX.V #TSXV #CanadianStocks #Healthcare #Pharma #Dividends #Buybacks
1
14
898
Anton | Specter retweeted
$BOSC is a no brainer at current price. My base case has them doing minimum $.80 EPS at least by 2030, and if you put a 10 P/E on it, then it would be an $8 stock. Could be substantially more if they make a good accretive acquisition. As @SCMRE111 also mentioned, the $/shekl is in their favor and is getting stronger. All their wages to employees are in Shekl, but the orders are usually USD, so this is a big tailwind, and will help drive earnings furthur.
$BOSC pay attn to this defense name. I’ve owned for 2 years. Know mgmt extremely well. They pre-ann a great 2H yday saying b/l up to 35m +45%. 20m+ to be delivered in 2H. Est is for 25m plus $/shekl in their favor for 1st time in awhile. Report 11/30. Can’t wait
1
3
27
3,611
Anton | Specter retweeted
Vusion $VU dévoile ses ambitions stratégiques à l’horizon 2030 ➡️ chiffre d’affaires confirmé à 2 milliards pour 2027, en croissance de 20 à 25% ➡️ chiffre d’affaires à 3 milliards en 2030 ➡️ Les VAS représenteront 40% du chiffre d’affaires en 2030 ➡️ 700 millions d’EBITDA en 2030 ➡️ contrat majeur annoncé en parallèle avec dm sur 2000 magasins avec la nouvelle génération EdgeSense OU EST LA FALAISE WALMART ? 😍
11
8
1
76
3,842
Anton | Specter retweeted
Who is the best person to follow for stocks on here? Bonus points if they are relatively unknown.
33
4
32
12,961
Anton | Specter retweeted
💣 Vusion $VU annonce ce jour une OPA sur Pricer, le numéro 4 mondial des ESL ➡️ Prix fixé à 88m€ pour un acteur qui fait plus de 200m€ de CA, une offre au rabais qui va rapporter gros ➡️ Vusion aurait avec Pricer plus de 50% du marché des ESL dans le monde ➡️ Grâce à ce coup de force, Vusion va récupérer les contrats majeurs de Pricer notamment avec IBM pour l’armée américaine ou encore avec Sobeys le numéro 2 Canadien, plus de 50 000 magasins dans le monde Vusion va TOUT prendre 🔥🔥🔥🔥
14
4
2
92
5,119
Anton | Specter retweeted
HII $HII AWARDED NAVY CONTRACT FOR LIONFISH UNMANNED UNDERSEA VEHICLES, POTENTIAL VALUE EXCEEDS $347M • Five-year contract • HII to deliver 175 Lionfish small unmanned undersea vehicles, with potential to scale to 200
2
7
3
97
8,673
$HROW Vevye TRx trends. This was accomplished with 50 reps, they recently increased to 140 reps. 2027 should see a huge ramp. You can reconstruct this using company data. Bloomberg data - one of the main reasons people are pessimistic - are flat out wrong. Mark talks about in the letter to stockholders... @EyeFarma
1
2
40
2,178
Anton | Specter retweeted
Qui est Dayton Judd, le patron de FitLife Brands ($FTLF), et pourquoi c’est une masterclass de management pour investir dans les small caps ? Un cas d'école de création de valeur discrète, loin du bruit de la tech. ⬇️
1
1
1
9
2,158
Anton | Specter retweeted
Eton Pharma $ETON Q3 2026 : un trimestre record, une guidance relevée, et un titre qui explose d'environ 20%. Les ventes atteignent 57,9 M$, en hausse de 158% sur un an et au dessus des 45,9 M$ attendus. C'est le premier trimestre complet avec…substack.com/profile/3329424…
1
1
3
1,043
Anton | Specter retweeted
Shift4 analyse du Q3 2026 Shift4 livre un Q3 conforme à sa propre guidance, avec un free cash flow record, mais abaisse brutalement le Q4 et décale son levier cible. Entre contradiction de la direction et mauvaise communication… Analyse : im2specter.substack.com/p/sh…
C’est de loin mon plus mauvais call. Le départ de Jared à la NASA et les turbulences dans le monde ont atomisé la boite. Mes excuses à ceux qui ont pu suivre ce call de merde. Btw ne jamais suivre un guignol sur les réseaux.
1
6
1,049
Anton | Specter retweeted
Shift4 analyse du Q3 2026 Shift4 livre un Q3 conforme à sa propre guidance, avec un free cash flow record, mais abaisse brutalement le Q4 et décale son levier cible. Entre contradiction de la direction et mauvaise communication… Analyse : im2specter.substack.com/p/sh…
1
5
991
Anton | Specter retweeted
Kraken Robotics : 102 M$ de nouvelles commandes, dont la plus grosse commande de sonar de son histoire Voyons la répartition de cette commande, le cumul des commandes 2026, les mots du PDG et ce que cela change pour notre thèse…substack.com/@im2specter/not… $PNG.V $KRKNF
1
9
1,473
Anton | Specter retweeted
Une société canadienne fondée en 1969 vient de signer pour plus de $1,8B d'acquisitions en quelques semaines. Elle fabrique des bras robotiques pour la Lune, des satellites en série et elle s'apprête à lancer sa propre constellation SAR commerciale. Son nom : $MDA Space. 🧵
2
1
7
1,403
Anton | Specter retweeted
Everyone that bought the $NVDA dip over the past two days.
4
11
1
215
8,183
Anton | Specter retweeted
Harrow $HROW - Analyse Q3 2026 Harrow a livré ses meilleurs chiffres commerciaux de l’histoire au Q3. Et cut sa guidance EBITDA de 60%. Ces deux réalités coexistent, et c’est précisément là qu’est l’opportunité ou le piège ! Analysons cela ici : im2specter.substack.com/p/ha…
1
866
Anton | Specter retweeted
Technogym (TGYM) 🇮🇹 Beau rebond depuis le support
Technogym (TGYM) 🇮🇹 Beau support hebdomadaire...
1
4
16
1,918
Anton | Specter retweeted
Some late but (I hope) useful reactions on $PNG.V's big announcement last week: - Covelya is 2x Kraken's size, but the order-split was 50-50 which is encouraging for the core business. - 60-40 defence-commercial is robust. - The $22M sonar order is most likely from HII's Remus 300 underwater vehicle, which you can literally see in the picture lol. Expect additional orders from this program. Valuation: Assuming they complete $425M revenue next 12 months, at 22-23% EBITDA margins - this puts them at 13x NTM EV/EBITDA. Very attractive for a company growing at this pace against a decade-long tailwind.
4
9
1
56
4,963
Anton | Specter retweeted
1/8 Kraken Robotics ($PNG.NE): My view after talking to funds and sell-side analysts in Canada who know the company very well. First, the sell-side has maintained extremely high price targets despite the recent drop. Analyst Benoit Poirier at Desjardins, whom I've met a few times and think highly of, has a $13 price target, meaning over 3.5x upside from today's price. This is one of the highest price targets relative to the share price I've seen in a while.
15
12
2
153
33,079
Anton | Specter retweeted
$HROW G-MELT: NDA now expected by YE26 (prior: 1H27) after the pre-NDA meeting with FDA. My math: a standard ~10-month review implies a potential FDA decision ~Oct–Nov 2027 (vs 1H28 before). Filing acceptance checkpoint ~Feb 2027. Long $HROW. Not investment advice.
1
1
14
16,363